Selected biotech news
Celltech Chiroscience, the recently merged biotechnology group, is to sell the loss-making Rapigene division which conducts rapid genetic analysis. Part of the gene-to-drug strategy of John Padfield, the former chief executive of Chiroscience, it was hoped that Rapigene would build up revenue from its Masscode system - a screening method for...